The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Merck Sharp & Dohme; Orion; Rakuten Pharma
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Merck Serono; Roche
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Janssen (Inst); Kura Oncology (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rakuten Pharma (Inst); Shattuck Labs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck Serono
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Exelixis; Imvax; Lilly; Merck; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Irene Braña
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - Bristol-Myers Squibb
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Iben Spanggaard
Stock and Other Ownership Interests - Genmab (I)
Research Funding - Incyte (Inst); Merck (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer
 
James M. Ford
Research Funding - AstraZeneca (Inst); Genentech (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
 
Monica Arnedos
Honoraria - AstraZeneca; Novartis; Novartis (Inst); Pfizer; Seagen
Consulting or Advisory Role - Abbvie
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche
 
Salomon M. Stemmer
Stock and Other Ownership Interests - canfite; CTG Pharma; DocBoxMD; tyrnovo; VYPE
Research Funding - AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); Geicam (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Teva (Inst); Tiziana Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - check point inhibitors; combo patent; ctg; vype
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER; Shire
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Roche
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - Merck Serono (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Roche; SERVIER
 
Christos Fountzilas
Research Funding - Astellas Pharma (Inst); Incyte (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst)
 
Jie Zhang
Employment - Puma Biotechnology
 
Feng Xu
Employment - Puma Biotechnology
 
Alshad S. Lalani
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris